Feed CPRX
CP

Catalyst Pharmaceuticals

CPRX · NASDAQ

$31.49 -0.02% (-$0.01)
Market Cap $3.85B
P/E Ratio 17.42x
Div. Yield -
ROE 23.65%

Bulios Fair Price

$43.13

37.0% upside

Trenutna cena

$31.49

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica CPRX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
4/9
Valuation
66 /100
Fair
P/E 17.42x
EV/EBITDA 11.12x
P/S 6.46x
Growth
100 /100
Growing
EPS growth 30.84%
Rev. growth 40.10%
FCF growth 21.60%
Profitability
100 /100
Strong
Gross margin 122.04%
Net margin 37.08%
Op. margin 44.83%
Quality
91 /100
Excellent
ROIC 19.67%
ROE 23.65%
ROA 19.29%
Debt
100 /100
Low
Debt/Equity 0.00x
Current ratio 7.10x
Net debt/EBITDA -2.70x
Stability
50 /100
Moderate
Beta 0.74x
Rev. volatility 37.15%
EPS volatility 62.81%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o CPRX
Online

O podjetju

Catalyst Pharmaceuticals, Inc. (CPRX) is an American biopharmaceutical company specializing in research, development, and commercialization of drugs for rare neurological disorders. With activities in biotechnology and pharmacology, Catalyst Pharmaceuticals is a key player in the world of innovative treatment approaches. Their research focuses on discovering new treatment options and therapies for patients with neurological disorders, such as Lambert-Eaton myasthenic syndrome (LEMS). The company aims to provide modern treatment solutions and improve the quality of life for patients with rare diseases. Catalyst Pharmaceuticals is characterized by expertise in pharmacology and neurology. Catalyst Pharmaceuticals, Inc. (CPRX) shares could be suitable for investors looking for an investment opportunity in the biopharmaceutical sector with a company that specializes in innovative treatment approaches and therapies for patients with rare neurological disorders.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Richard John Daly

Employees

182

Headquarters

Coral Gables

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.